Showing 4781-4790 of 9576 results for "".
- Study: Cost of AD Care Higher in Low-Income Areashttps://practicaldermatology.com/news/study-cost-of-ad-care-higher-in-low-income-areas/2475282/Recommended skin care products for atopic dermatitis (AD) were found to be more expensive and less accessible in lower-income neighborhoods, new research in the Journal of Drugs in Dermatology indicates. "Pharmacy des
- Aesthetic Management Partners Launches New Non-Surgical Skin Revitalization Systemhttps://practicaldermatology.com/news/aesthetic-management-partners-launches-new-non-surgical-skin-revitalization-system/2475272/Aesthetic Management Partners announced the launch of PLADUOpro, a dual argon and nitrogen gas plasma system designed for advanced skin restoration, earlier this month.
- Analysis: No Added MACE Risk With Ustekinumab in Psoriasis and PsAhttps://practicaldermatology.com/news/analysis-no-added-mace-risk-with-ustekinumab-in-psoriasis-and-psa/2475231/New research suggests no difference in the risk of major adverse cardiovascular events (MACE) among patients with psoriasis (PsO) and psoriatic arthritis (PsA) initiating ustekinumab compared to adalimumab, etanercept, or secukinumab.
- Elevated IFN Signatures Seen in Nonlesional Skin of Cutaneous Lupus Erythematosus Patientshttps://practicaldermatology.com/news/elevated-ifn-signatures-seen-in-nonlesional-skin-of-cle-patients/2475210/Patients with systemic lupus erythematosus (SLE) and a history of cutaneous lupus erythematosus (CLE) showed elevated interferon-stimulated gene (ISG) expression in blood and nonlesional skin, according to a new study. The si
- Midmark Announces First USAB Compliant Procedure Chairhttps://practicaldermatology.com/news/Midmark-Announces-First-USAB-Compliant-Procedure-Chair/2475173/Midmark Corp. announced the launch of the Midmark 631 procedure chair, which the company said is the first US Access Board (USAB) compliant procedure chair. In 2024, the U.S. Access Board issued a new standard establishing design criteria for examination and procedure chairs, as well
- Study: Lotion Shows Efficacy in Treating Hyperkeratotic Plaque Psoriasishttps://practicaldermatology.com/news/hptaz-lotion-shows-efficacy-in-treating-hyperkeratotic-plaque-psoriasis/2475106/HP/TAZ lotion significantly improved hyperkeratotic psoriatic plaques in subgroups, according to recent data from a post hoc analysis of phase 3 trials. The authors of the post hoc analysis pooled data from two eight-week, v
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma by 2050https://practicaldermatology.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-by-2050/2474797/The global burden of skin cancer among adults aged 65 and older has increased steadily over the past three decades and is expected to continue rising through 2050, according to a new analysis of Global Burden of Disease (GBD) Study data.
- GW Prior Certification Coordinator Offers Tips at ElderDermhttps://practicaldermatology.com/news/GW-Prior-Certification-Coordinator-Offers-Tips-ElderDerm/2474666/There are no shortcuts to getting dermatologic treatments authorized by Medicaid and insurance companies, George Washington University Department of Dermatology’s prior certification coordinator said at the ElderDerm 2025 Conference in Washington, DC. Effort and diligence are the keys when
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
- Study: Nonprescription Balm Performs on Par with Topical Antibiotichttps://practicaldermatology.com/news/study-nonprescription-balm-performs-on-par-with-topical-antibiotic/2474439/A new randomized controlled trial found that a nonprescription repairing balm containing panthenol, madecassoside, and metal salts (CB5) performs equivalently to a topical antibiotic (PSO) for wound healing after cryotherapy of actinic keratoses (AKs).